Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system
Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab Emirates
Boston, MA, May 16, 2023 (GLOBE NEWSWIRE) -- Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development of the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability. Mass General Brigham and Dana-Farber Cancer Institute are strategic partners, serving in an advisory capacity, on the project in Sharjah, United Arab Emirates, which includes a multi-specialty flagship hospital for integrated, cutting-edge care.
The collaboration combines the depth and breadth of clinical expertise and innovation from Mass General Brigham and Dana-Farber Cancer Institute, with BEEAH’s vision to create a sustainable, advanced, patient-centered health system designed to deliver care to patients within – and beyond – hospital walls. BEEAH Group was founded in 2007 to tackle sustainability challenges in Sharjah and improve quality of life.
Focused on serving the unique needs of the people of Sharjah and the region, the Jawaher Boston Medical District will offer patients access to the latest clinical expertise across a wide variety of integrated clinical specialties, including lifestyle medicine and prevention, oncology, women’s health, pediatrics, cardiovascular, neurosciences, behavioral health, and rehabilitation medicine. In addition to medical and research expertise, Mass General Brigham and Dana-Farber Cancer Institute will also collaborate with BEEAH Group to advise on best practices in workforce training, development, and public education to the community, with attention to developing local talent.
Mass General Brigham and Dana-Farber Cancer Institute are advising BEEAH Group in their development of multiple facilities, comprising the flagship hospital and ambulatory clinics across Sharjah, with integrated, innovative, and digital solutions, including app-based care and hospital-at-home.
“Mass General Brigham has a deep history of global collaboration aimed at serving and improving the lives of patients around the world,” said Raymond W. Liu, MD, Vice President, Mass General Brigham Global Advisory. “In collaborating with BEEAH, we hope to contribute our decades of expertise to their development of a unique, innovative vision for a health system that builds on medicine’s leading edge, with an eye to the future.”
“Dana-Farber, a world leader in cancer treatment and research, is committed to advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases locally and globally,” said Adam Reich, Vice President of Business Initiatives at Dana-Farber Cancer Institute. “We are pleased to work with BEEAH and extend our expertise to this collaboration as part of our mission to enhance access to expert cancer care and reduce the burden of cancer worldwide.”
By leveraging its expertise in quality-of-life solutions in Sharjah and the Middle East, BEEAH will create a new destination for the health, wellness and quality of life for the people of Sharjah and the region focused on patient outcomes and experience gleaned from a robust academic ecosystem pioneered, developed and refined over two centuries by Mass General Brigham and Dana-Farber Cancer Institute clinicians.
By pooling their combined medical, research and sustainability expertise, Mass General Brigham, Dana-Farber Cancer Institute and BEEAH will develop innovative technologies, diagnostics, delivery models and patient care, ultimately fostering research, directly benefitting patients globally and providing valuable cross-institutional learnings in the United States. The outcome will enable BEEAH to create a comprehensive patient-centered health care system for the people of Sharjah and the UAE, integrating healthcare solutions into homes, schools, workplaces, and communities to help all patients and their families live healthier lives.
“By partnering with Mass General Brigham and Dana-Farber Cancer Institute, BEEAH Group is entering the healthcare industry and adding a new dimension to our purpose of pioneering a sustainable quality of life for the people of Sharjah, the UAE, and beyond,” said Khaled Al Huraimel, Group CEO of BEEAH Group. “Drawing from the expertise of our partners in Boston, we look forward to creating not just an integrated health network, but a future-ready healthcare ecosystem. The Jawaher Boston Medical District will provide patients in Sharjah access to world-class healthcare closer to home, while also serving as a hub for the development of cutting-edge treatments and medical advancement.”
The project draws from Mass General Brigham and Dana-Farber Cancer Institute’s medical and research expertise, as well as BEEAH Group’s experience collaborating and innovating with international partners to create facilities that are sustainable, digitally-enabled and centered around the comfort and convenience of occupants.
Following a meeting of representatives from Mass General Brigham, Dana-Farber Cancer Institute and BEEAH Group, Sheikha Jawaher Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of BEEAH Group, and Meghan Gregonis, United States General Consul in Dubai, the Jawaher Boston Medical District in Sharjah was approved to move forward.
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit www.massgeneralbrigham.org.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber is the only hospital with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
For more information, please visit www.dana-farber.org.
About BEEAH Group
BEEAH Group is the region’s leading sustainability and digitalisation expert, renowned for ground-breaking environmental innovations and smart solutions for future-ready cities. Recognising sustainability and technology as the pillars of a modern economy, BEEAH Group has invested in a comprehensive, full-circle strategy for the future. BEEAH Group operates in the industries of waste management, renewable energy, technology, consulting, education, transport, real estate and healthcare. Raising the bar for the quality of life in the region, BEEAH Group businesses continue to set industry benchmarks in sustainable, smart solutions and help countries across the region create and execute their roadmap for a socially responsible future. The Group currently operates in the UAE, Egypt and KSA. For more information, please visit www.beeahgroup.com and connect on LinkedIn, Instagram, Facebook and Twitter @beeahgroup
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu
Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding
September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202
Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release
September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th
Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse
Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er